BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun W, Kirkpatrick E, Ermler M, Nachbagauer R, Broecker F, Krammer F, Palese P. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach. J Virol 2019;93:e00333-19. [PMID: 30944178 DOI: 10.1128/JVI.00333-19] [Cited by in Crossref: 28] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Pardi N, Carreño JM, O'Dell G, Tan J, Bajusz C, Muramatsu H, Rijnink W, Strohmeier S, Loganathan M, Bielak D, Sung MMH, Tam YK, Krammer F, McMahon M. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat Commun 2022;13:4677. [PMID: 35945226 DOI: 10.1038/s41467-022-32149-8] [Reference Citation Analysis]
2 Wang WC, Sayedahmed EE, Sambhara S, Mittal SK. Progress towards the Development of a Universal Influenza Vaccine. Viruses 2022;14:1684. [PMID: 36016306 DOI: 10.3390/v14081684] [Reference Citation Analysis]
3 Song Y, Zhu W, Wang Y, Deng L, Ma Y, Dong C, Gonzalez GX, Kim J, Wei L, Kang S, Wang B. Layered protein nanoparticles containing influenza B HA stalk inducted sustained cross-protection against viruses spanning both viral lineages. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121664] [Reference Citation Analysis]
4 Tsybalova LM, Stepanova LA, Ramsay ES, Vasin AV. Influenza B: Prospects for the Development of Cross-Protective Vaccines. Viruses 2022;14:1323. [PMID: 35746794 DOI: 10.3390/v14061323] [Reference Citation Analysis]
5 Li L, Changrob S, Fu Y, Stovicek O, Guthmiller JJ, McGrath JJC, Dugan HL, Stamper CT, Zheng NY, Huang M, Wilson PC. Librator: a platform for the optimized analysis, design, and expression of mutable influenza viral antigens. Brief Bioinform 2022:bbac028. [PMID: 35183062 DOI: 10.1093/bib/bbac028] [Reference Citation Analysis]
6 Gravel C, Muralidharan A, Duran A, Zetner A, Pfeifle A, Zhang W, Hashem A, Tamming L, Farnsworth A, Loemba H, Chen W, Krammer F, Safronetz D, Cao J, Wang L, Sauve S, Rosu-Myles M, Van Domselaar G, Li X. Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages. iScience 2021;24:103328. [PMID: 34805790 DOI: 10.1016/j.isci.2021.103328] [Reference Citation Analysis]
7 Liu Y, Strohmeier S, González-Domínguez I, Tan J, Simon V, Krammer F, García-Sastre A, Palese P, Sun W. Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice. Front Immunol 2021;12:746447. [PMID: 34603333 DOI: 10.3389/fimmu.2021.746447] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Cardenas-Garcia S, Cáceres CJ, Jain A, Geiger G, Mo JS, Jasinskas A, Nakajima R, Rajao DS, Davies DH, Perez DR. FluB-RAM and FluB-RANS: Genome Rearrangement as Safe and Efficacious Live Attenuated Influenza B Virus Vaccines. Vaccines (Basel) 2021;9:897. [PMID: 34452022 DOI: 10.3390/vaccines9080897] [Reference Citation Analysis]
9 Roubidoux EK, Schultz-Cherry S. Animal Models Utilized for the Development of Influenza Virus Vaccines. Vaccines (Basel) 2021;9:787. [PMID: 34358203 DOI: 10.3390/vaccines9070787] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Narkhede YB, Gonzalez KJ, Strauch EM. Targeting Viral Surface Proteins through Structure-Based Design. Viruses 2021;13:1320. [PMID: 34372526 DOI: 10.3390/v13071320] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 White CL, Chiem K, Perez DR, Santos J, Cardenas Garcia S, Nogales A, Martínez-Sobrido L. A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines. Viruses 2021;13:1278. [PMID: 34208979 DOI: 10.3390/v13071278] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Zeigler DF, Gage E, Clegg CH. Epitope-targeting platform for broadly protective influenza vaccines. PLoS One 2021;16:e0252170. [PMID: 34043704 DOI: 10.1371/journal.pone.0252170] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
13 Nguyen QT, Choi YK. Targeting Antigens for Universal Influenza Vaccine Development. Viruses 2021;13:973. [PMID: 34073996 DOI: 10.3390/v13060973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Boyoglu-Barnum S, Ellis D, Gillespie RA, Hutchinson GB, Park YJ, Moin SM, Acton OJ, Ravichandran R, Murphy M, Pettie D, Matheson N, Carter L, Creanga A, Watson MJ, Kephart S, Ataca S, Vaile JR, Ueda G, Crank MC, Stewart L, Lee KK, Guttman M, Baker D, Mascola JR, Veesler D, Graham BS, King NP, Kanekiyo M. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 2021;592:623-8. [PMID: 33762730 DOI: 10.1038/s41586-021-03365-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 46] [Article Influence: 14.0] [Reference Citation Analysis]
15 Nagashima KA, Mousa JJ. Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine. Viruses 2021;13:546. [PMID: 33805245 DOI: 10.3390/v13040546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Bullard BL, Weaver EA. Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine. Vaccines (Basel) 2021;9:257. [PMID: 33805749 DOI: 10.3390/vaccines9030257] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
17 Sangesland M, Lingwood D. Antibody Focusing to Conserved Sites of Vulnerability: The Immunological Pathways for 'Universal' Influenza Vaccines. Vaccines (Basel) 2021;9:125. [PMID: 33562627 DOI: 10.3390/vaccines9020125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
18 Kerstetter LJ, Buckley S, Bliss CM, Coughlan L. Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses. Front Immunol 2020;11:607333. [PMID: 33633727 DOI: 10.3389/fimmu.2020.607333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
19 McMillan CLD, Young PR, Watterson D, Chappell KJ. The Next Generation of Influenza Vaccines: Towards a Universal Solution. Vaccines (Basel) 2021;9:26. [PMID: 33430278 DOI: 10.3390/vaccines9010026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
20 Nachbagauer R, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Stadlbauer D, Wilson PC, Aydillo T, Behzadi MA, Bhavsar D, Bliss C, Capuano C, Carreño JM, Chromikova V, Claeys C, Coughlan L, Freyn AW, Gast C, Javier A, Jiang K, Mariottini C, McMahon M, McNeal M, Solórzano A, Strohmeier S, Sun W, Van der Wielen M, Innis BL, García-Sastre A, Palese P, Krammer F. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med 2021;27:106-14. [PMID: 33288923 DOI: 10.1038/s41591-020-1118-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 74] [Article Influence: 15.5] [Reference Citation Analysis]
21 Kirkpatrick E, Henry C, McMahon M, Jiang K, Strohmeier S, van Bakel H, Wilson PC, Krammer F. Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity. J Virol 2020;94:e01185-20. [PMID: 32907980 DOI: 10.1128/JVI.01185-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Sun W, Luo T, Liu W, Li J. Progress in the Development of Universal Influenza Vaccines. Viruses 2020;12:E1033. [PMID: 32957468 DOI: 10.3390/v12091033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
23 Du R, Cui Q, Rong L. Flu Universal Vaccines: New Tricks on an Old Virus. Virol Sin 2021;36:13-24. [PMID: 32870450 DOI: 10.1007/s12250-020-00283-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Wei CJ, Crank MC, Shiver J, Graham BS, Mascola JR, Nabel GJ. Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov 2020;19:239-52. [PMID: 32060419 DOI: 10.1038/s41573-019-0056-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 79] [Article Influence: 25.5] [Reference Citation Analysis]
25 Vogel OA, Manicassamy B. Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics. Front Microbiol 2020;11:135. [PMID: 32117155 DOI: 10.3389/fmicb.2020.00135] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
26 Mesin L, Schiepers A, Ersching J, Barbulescu A, Cavazzoni CB, Angelini A, Okada T, Kurosaki T, Victora GD. Restricted Clonality and Limited Germinal Center Reentry Characterize Memory B Cell Reactivation by Boosting. Cell 2020;180:92-106.e11. [PMID: 31866068 DOI: 10.1016/j.cell.2019.11.032] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 23.3] [Reference Citation Analysis]
27 Virk RK, Jayakumar J, Mendenhall IH, Moorthy M, Lam P, Linster M, Lim J, Lin C, Oon LLE, Lee HK, Koay ESC, Vijaykrishna D, Smith GJD, Su YCF. Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity. Proc Natl Acad Sci U S A 2020;117:619-28. [PMID: 31843889 DOI: 10.1073/pnas.1916585116] [Cited by in Crossref: 25] [Cited by in F6Publishing: 44] [Article Influence: 8.3] [Reference Citation Analysis]
28 Jang YH, Seong BL. The Quest for a Truly Universal Influenza Vaccine. Front Cell Infect Microbiol 2019;9:344. [PMID: 31649895 DOI: 10.3389/fcimb.2019.00344] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
29 Sun W, Zheng A, Miller R, Krammer F, Palese P. An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains. Vaccines (Basel) 2019;7:E117. [PMID: 31540436 DOI: 10.3390/vaccines7030117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
30 Broecker F, Liu STH, Suntronwong N, Sun W, Bailey MJ, Nachbagauer R, Krammer F, Palese P. A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. NPJ Vaccines 2019;4:31. [PMID: 31341648 DOI: 10.1038/s41541-019-0126-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
31 Behzadi MA, Stein KR, Bermúdez-González MC, Simon V, Nachbagauer R, Tortorella D. An Influenza Virus Hemagglutinin-Based Vaccine Platform Enables the Generation of Epitope Specific Human Cytomegalovirus Antibodies. Vaccines (Basel) 2019;7:E51. [PMID: 31207917 DOI: 10.3390/vaccines7020051] [Reference Citation Analysis]